At the news
? BULLISHIMPACT 8/10 8-K filed Apr 27, 2026 at 08:05 ET
CorMedix announced positive topline results from its Phase III ReSPECT trial for REZZAYO (rezafungin) as prophylaxis against invasive fungal infections in high-risk transplant patients. The study met its primary endpoint of non-inferiority in fungal-free survival at Day 90 (60.7% for rezafungin vs. 59.0% for standard therapy) and showed favorable safety outcomes in secondary endpoints, including fewer toxicity-related discontinuations and drug-drug interactions. The company plans to submit a supplemental New Drug Application (sNDA) to the FDA in the second half of 2026.
- Phase III ReSPECT trial met primary endpoint of non-inferiority in fungal-free survival at Day 90: 60.7% for rezafungin vs. 59.0% for standard antimicrobial regimen.
- Rezafungin demonstrated a favorable safety profile with benefits in secondary endpoints, including fewer treatment-emergent adverse events leading to discontinuation.
- The trial was sponsored by Mundipharma, which holds commercial rights outside the U.S.; Melinta Therapeutics (a CorMedix subsidiary) will handle U.S. distribution.
- CorMedix and partners anticipate a pre-NDA meeting with the FDA in the coming months, with a target sNDA submission in 2H26.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access